INTRODUCTION {#sec1-1}
============

Severe acute respiratory syndrome (SARS) is an emerging infectious disease characterized by systemic inflammation followed by atypical pneumonia \[Peiris et al., [2003b](#bib20){ref-type="ref"}\]. Shortly after the initial worldwide outbreak in 2003, SARS‐associated coronavirus (SARS‐CoV) was discovered as an etiological agent of SARS \[Drosten et al., [2003](#bib6){ref-type="ref"}; Ksiazek et al., [2003](#bib13){ref-type="ref"}; Kuiken et al., [2003](#bib14){ref-type="ref"}; Peiris et al., [2003a](#bib19){ref-type="ref"}\], and then angiotensin‐converting enzyme 2 (ACE2) was identified as a functional receptor of this newly arrived virus \[Li et al., [2003](#bib16){ref-type="ref"}\]. More recently, CD209L was reported as being another alternative receptor for the virus, but it appears to be a less efficient entry site than ACE2 \[Jeffers et al., [2004](#bib12){ref-type="ref"}\].

Virus receptors generally play a key role in the entry of the pathogen into the host cells and may influence development or progression of viral diseases. For example, it is well known that genetic polymorphism of chemokine receptor 5 (CCR5), a co‐receptor for human immunodeficiency virus‐1 (HIV‐1), influences the natural history of HIV‐1 infection. The mutant allele CCR5‐Δ32 does not produce a functional protein and has been shown to protect host cells against HIV‐1 infection, and progression into acquired immunodeficiency syndrome is delayed after seroconversion takes place \[Dean et al., [1996](#bib3){ref-type="ref"}; Liu et al., [1996](#bib17){ref-type="ref"}; Samson et al., [1996](#bib21){ref-type="ref"}\]. By analogy with the above, we considered that genetic polymorphisms of ACE2 could influence SARS‐CoV infection or clinical manifestations of SARS.

ACE2 is a homologue of ACE1 and exhibits 40% identity of amino acid sequence to its N‐ and C‐terminal domains \[Tipnis et al., [2000](#bib22){ref-type="ref"}\]. Similar to ACE1, ACE2 is a metalloprotease that constitutes a renin‐angiotensin system. Human full‐length ACE2 cDNAs have been cloned already from lymphoma (GenBank accession No. AF241254) \[Tipnis et al., [2000](#bib22){ref-type="ref"}\], cardiac left ventricle (AF291820) \[Donoghue et al., [2000](#bib4){ref-type="ref"}\] and testis (AY623811) \[Douglas et al., [2004](#bib5){ref-type="ref"}\]. Based on published data, it has been said that the ACE2 gene (*ACE2*) contains 18 exons, and spans approximately 40 kb of genomic DNA on the human X‐chromosome. Although *ACE2* mRNA expressions were demonstrated in the lung by the method of quantitative reverse transcription‐PCR (RT/PCR) \[Harmer et al., [2002](#bib10){ref-type="ref"}\] and its protein expression was obviously shown by immunohistochemistry \[Hamming et al., [2004](#bib9){ref-type="ref"}\], full‐length *ACE2* cDNA has not been cloned from the lung so far. This is considered to be very likely as being an important replication site of SARS‐CoV \[Haagmans et al., [2004](#bib8){ref-type="ref"}\].

In the present study, we attempted a full‐length cloning of *ACE2* cDNA from the human lung and found a new alternative, the 5′‐untranslated exon. During this process, an extended region of the original exon 1 was identified in the testis\' RNAs. Then, we explored genetic polymorphisms within 19 exons including new regions and the 5′‐flanking region of *ACE2* and tried to determine whether the polymorphisms of *ACE2* are associated with SARS in Vietnamese.

MATERIALS AND METHODS {#sec1-2}
=====================

Cloning of ACE2 cDNA From the Lung {#sec2-1}
----------------------------------

Cloning was performed by combination of RT/PCR and 5′‐ and 3′‐ rapid amplification of cDNA ends (RACE) procedures, using human lung total RNA (Stratagene, La Jolla, CA) and human testis total RNA (Stratagene) as a control. The total RNAs were reverse‐transcribed using SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA) with oligo(dT)~12--18~, and then cDNA was amplified using Platinum Taq DNA Polymerase High Fidelity (Invitrogen) with primers ACE2‐exon 1s (5′‐CAA AGG CTG ATA AGA GAG AA‐3′) and ACE2‐exon 18 as (5′‐GAA CAG AAG TCA AAT CCA GA‐3′) to amplify the transcript of 2721 bp encompassing the original 18 exons of *ACE2* gene on database.

The First Choice RLM‐RACE Kit (Ambion, Austin, TX) was used for 5′‐ and 3′‐RACE procedures following the manufacturer\'s recommendation. Gene‐specific primer sets for 5′‐RACE were ACE2‐5′Outer1 and ACE2‐5′Inner1 (5′‐GTG GAT ACA TTT GGG CAA GT‐3′ and 5′‐CCT AGA CTA AAA CCT CCT CA‐3′), and ACE2‐5′Outer2 and ACE2‐5′Inner2 (5′‐GAA GTA AGA AAG CCT CCA CA‐3′ and 5′‐CTC CTG ATC CTC TGT AGC CA‐3′). Gene specific primer set for 3′‐RACE was ACE2‐3′Outer and ACE2‐3′Inner (5′‐CAA TGA TGC TTT CCG TCT GA‐3′ and 5′‐ACA CTT GGA CCT CCT AAC CA‐3′). Nucleotide sequences of PCR products were directly determined by the automated DNA sequencer (PRISM 3100 Genetic Analyzer, Applied Biosystems, Foster City, CA).

To investigate expression of the exons on the 5′ side, RT/PCR procedures were performed on the total RNAs of human lung, testis, trachea (Stratagene), primary‐cultured bronchial epithelial cells \[Lechner and LaVeck, [1985](#bib15){ref-type="ref"}\], small intestine (Ambion), and on the human major organ cDNAs (Bio Chain Institute) with the sense primer New‐exon (5′‐TTC TTA CTT CCA CGT GAC CT‐3′) or Extended‐exon 1 (5′‐GCT CAG CAG ATT GTT TAC TG‐3′) and the antisense primer ACE2‐5′Outer1.

Genomic DNA Samples for the Association Study {#sec2-2}
---------------------------------------------

An association study between SARS patients and controls was reviewed and approved by local ethics committees. Of 62 cases fulfilling the World Health Organization case definition of probable SARS in Vietnam \[WHO, [2003](#bib24){ref-type="ref"}\], 5 fatal cases and 3 non‐Vietnamese cases were excluded from this study. In the remaining 54 cases, 44 individuals agreed to participate in this study as cases. One hundred and three Vietnamese staff members, who did not develop SARS but may have come in contact with SARS patients in the hospital where nosocomial infection of SARS had arisen, were enrolled as contacts. Furthermore, 50 medical staff members who had been working in a separate building and those considered having no history of contact with SARS patients joined in this study as non‐contacts, according to information obtained by questionnaire. Peripheral blood samples of all the subjects were collected and genomic DNA was extracted from the blood cells by a method described elsewhere \[Wang et al., [1994](#bib23){ref-type="ref"}\].

Testing for Antibody Response to the SARS‐CoV {#sec2-3}
---------------------------------------------

To detect the antibody to the SARS‐CoV in serum, all the blood samples were tested with SARS ELISA (Genelabs Diagnostics Pte. Ltd., Singapore Science Park, Singapore) in accordance with the manufacturer\'s recommendation \[Guan et al., [2004](#bib7){ref-type="ref"}\].

Identification of Polymorphisms Within *ACE2* Gene {#sec2-4}
--------------------------------------------------

Of the 44 SARS cases and 103 contacts recruited, a half of the samples were randomly selected for searching polymorphisms within the *ACE2* gene. PCR primers were designed to amplify 19 exons including the new alternative exon, exon‐intron boundaries and approximately 1,000 bp of the 5′‐flanking region of the new exon, reaching 2,000 bp upstream of the 5′‐end of the original exon 1 (Table [I](#tbl1){ref-type="table"}). Genomic DNA of each sample was subjected to PCR amplification followed by direct sequencing.

###### 

Primers Used to Identify Polymorphisms Within the *ACE2* Gene

  Region               Primer name         Primer sequence (5′--3′)                             Product size
  -------------------- ------------------- ---------------------------------------------------- --------------
  5′ flanking region   ACE2‐pro‐1‐sense    TAA TTC AGT CAG TGC TTG C                            676 bp
                       ACE2‐pro‐1‐anti     AAT AGT GGA GGC ATA GAT AAA                          
  5′ flanking region   ACE2‐pro‐2‐sense    TTT GTG AGC TGC TTT ATT TT                           618 bp
                       ACE2‐pro‐2‐anti     TGC CAG AGT GTA TGT ATG AG                           
  New alternate exon   ACE2‐new‐sense      TTA TTG CAA TGT CAC CTG A                            470 bp
                       ACE2‐new‐anti       TTA TGA CTA CTC TCC ACT CCA                          
  5′ flanking region   ACE2‐pro‐3‐sense    TTT GAA TAG GTA AGT GAA GG                           669 bp
                       ACE2‐pro‐3‐anti     TAG AAC TAG GGA TCA TGA AGA                          
  5′ flanking region   ACE2‐pro‐4‐sense    TGA ATT CCA TAA AGA CAA GG                           653 bp
                       ACE2‐pro‐4‐anti     AAA CTT GTC CAA AAA TGT CTT                          
  Exon 1               ACE2‐ex1‐sense      ATC TTT AAC AGC TTT CTA GGA                          644 bp
                       ACE2‐ex1‐anti       AAC ATC CAA TCT CAC AAC TC                           
  Exon 2               ACE2‐ex2‐sense      AAC TCA TCT ATG TCA CAG CAC                          636 bp
                       ACE2‐ex2‐anti       AAA TTA TAT GGA CAC CTT ACC                          
  Exon 3               ACE2‐ex3‐sense      ACT TCT TTG GGT TTT GGT AG ACA TCA GGT CAT AAA GTG   627 bp
                       ACE2‐ex3‐anti       GTT                                                  
  Exon 4               ACE2‐ex4‐sense      TCA TTT CAG TGG TTT ATT TTC                          521 bp
                       ACE2‐ex4‐anti       CTT TTC TTT TTC CCC AGT A                            
  Exon 5               ACE2‐ex5‐sense      CTT GTA TGG TTC TTG TGC TT                           535 bp
                       ACE2‐ex5‐anti       GGG CTG TCC TAT TAT TCT CTA                          
  Exon 6               ACE2‐ex6‐sense      ACC TGT GTT CTC CCA AGT A                            568 bp
                       ACE2‐ex6‐anti       CTT TAT CAT TTG AAT TGC AG                           
  Exon 7               ACE2‐ex7‐sense      TCA CCA AGT TAA GTA CAC GAA                          562 bp
                       ACE2‐ex7‐anti       TAC ACC TGC AAT TCA AGT TAT                          
  Exon 8               ACE2‐ex8‐1‐sense    TTG CAG TGA GAA CAT TTG AAA                          560 bp
                       ACE2‐ex8‐1‐anti     CCT CTG TTG TCT CCC ATT T                            
  Exon 8               ACE2‐ex8‐2‐sense    GCT GTG CAG TAG ATC TCA AA                           643 bp
                       ACE2‐ex8‐2‐anti     CAG ATT GTC CAC AGG TTC A                            
  Exon 9               ACE2‐ex9‐sense      CTA TGA GCA AGA GAA CAG G                            577 bp
                       ACE2‐ex9‐anti       TCA CCA GTA GTA ATT TCC AGT                          
  Exon 10              ACE2‐ex10‐sense     AGG GAG GAA ACT GAA ACT AAT                          587 bp
                       ACE2‐ex10‐anti      GGT ATC CAA ATG GAG ACT AAA                          
  Exon 11              ACE2‐ex11‐sense     GTG CAC ACC TAT AAA CCA AG                           615 bp
                       ACE2‐ex11‐anti      TGA GCA TGT TTA GGG TAG AC                           
  Exon 12              ACE2‐ex12‐sense     GTG AAA GGG CTA TTA ATC TGT                          612 bp
                       ACE2‐ex12‐anti      GAG AGG GCT GTA GTT ATG A                            
  Exon 13              ACE2‐ex13‐sense     CAG GAA CCT AGA CCA TAC AA                           636 bp
                       ACE2‐ex13‐anti      GTT GCT TTC ACT ATG TCT CA                           
  Exon 14              ACE2‐ex14‐sense     GTA CAA ATT AGG TCA TGG C                            550 bp
                       ACE2‐ex14‐anti      GAC GAG AGT CAA TTG AAA G                            
  Exon 15              ACE2‐ex15‐sense     ATT ATT GGG TTT CAT CTC G                            637 bp
                       ACE2‐ex15‐anti      TAT AGG TCA ATG AAG GCA G                            
  Exon 16              ACE2‐ex16‐sense     CAG AAC AAA TAG TGC CAA A                            610 bp
                       ACE2‐ex16‐anti      CAT AGT GGT AAC TTG CTT GAT                          
  Exon 17              ACE2‐ex17‐sense     GCT CTG TCA CCT AGG CTA G                            633 bp
                       ACE2‐ex17‐anti      CTA GGA AGA TGA ACT GCT GAT                          
  Exon 18              ACE2‐ex18‐1‐sense   TTA AGA TGA ATC CTA GCA GTG                          655 bp
                       ACE2‐ex18‐1‐anti    CAT TTA GAT TAT CCC TGA ACA                          
  Exon 18              ACE2‐ex18‐2‐sense   TCT GGA TTT GAC TTC TGT TC                           623 bp
                       ACE2‐ex18‐2‐anti    AAC ACT GTG AGC AAA TAC AAA                          
  Exon 18              ACE2‐ex18‐3‐sense   GAA CAG GTA GAG GAC ATT G                            531 bp
                       ACE2‐ex18‐3‐anti    GGG TAG TGA CTG TGA GAA ATA                          
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Genotyping of Identified Polymorphisms {#sec2-5}
--------------------------------------

Non‐synonymous nucleotide substitutions and other variations with a minor allele frequency higher than 0.05 were subjected to genotyping in all SARS cases, contacts and non‐contacts. Consequently, one novel non‐synonymous substitution, two possible non‐synonymous polymorphisms in the database (dbSNP identification nos. rs4646116 and rs11798104), and variations of 3′‐UTR in exon 18 (position 39844) and of intron 3 (rs2285666, position 8789) were genotyped by the combination of direct sequencing method and single‐strand conformation polymorphism (SSCP) analysis or PCR‐based restriction fragment length polymorphism (RFLP) analysis.

Statistical Analysis {#sec2-6}
--------------------

Disease associations were assessed by the chi‐square test. The *P* values less than 0.05 were considered significant in all the tests and data analysis was carried out using JMP version 5 (SAS Institute, Inc., Cary, NC).

RESULTS {#sec1-3}
=======

Full‐Length ACE2 cDNAs From the Lung and Expression of the Transcripts {#sec2-7}
----------------------------------------------------------------------

By the use of the RT/PCR encompassing all known exons of *ACE2* and 3′‐RACE method, we could amplify *ACE2* cDNA as PCR fragments completely corresponding to the published sequence of *ACE2* cDNA (AF241254). The 5′‐RACE procedure on the total RNA of the lung demonstrated the presence of a new alternative exon (registered as AB193259), which consisted of a segment between position −1141 and −942 and was connected to the 5′‐end of the original exon 1. The 5′‐end of transcripts was extended to position −1141 repeatedly by both sets of gene‐specific primers. In addition, novel 65 nucleotides on the 5′‐side (registered as AB193260), extending the 5′‐end of the original exon 1 upstream, were amplified from the total RNA of testis. A schematic diagram of the exon‐intron structure is shown in Figure [1](#fig1){ref-type="fig"}.

![A schematic diagram of the *ACE2* gene structure and the positions of SNPs. The known exons are depicted as open boxes. A solid box and a striped box indicate the new exon and the new extended region of the exon 1, respectively. The arrows represent locations of the SNPs analyzed in a case‐control study. The broken line depicts an alternative‐splicing site.](AJMG-136A-52-g001){#fig1}

RT‐PCR revealed that the expression of the new alternative exon could be seen not only in the lung but also in the testis, trachea, bronchial epithelial cells, small intestine, and various major organs (data not shown). The new extended region was expressed not only in the testis but also in other organs including bronchial epithelial cells and the small intestine (data not shown).

Subgrouping of Subjects Based on the Status of Anti‐SARS‐CoV Antibody {#sec2-8}
---------------------------------------------------------------------

Basic characteristics and sub‐grouping of subjects are shown in Table [II](#tbl2){ref-type="table"}. The 44 SARS cases, 103 contacts, and 50 non‐contacts were analyzed in the present study. Based on anti‐SARS‐CoV antibody titer in serum, the contacts were further divided into two subgroups, antibody‐positive contacts, and antibody‐negative contacts (data not shown).

###### 

Demographic Findings of Subjects and Subgroups

  Groups                        SARS cases (n = 44)   Contacts (n = 103)   Anti‐SARS‐CoV antibody   Non‐contacts (n = 50)   
  ----------------------------- --------------------- -------------------- ------------------------ ----------------------- -----------------------------
  Age (years), mean \[range\]   39.3 \[17--76\]       36.5 \[15--68\]      36.0 \[25--50\]          36.6 \[15--68\]         ---[a](#fn1){ref-type="fn"}
  Male/female                   13/31                 46/57                7/9                      39/48                   17/33

Data not available.
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Identification of Polymorphisms Within *ACE2* Gene {#sec2-9}
--------------------------------------------------

All exons including the new exon, exon‐intron boundaries and the corresponding 5′‐flanking region of *ACE2* were tested to identify variations of *ACE2* among SARS cases and contacts. As shown in Table [III](#tbl3){ref-type="table"}, 19 single nucleotide polymorphisms (SNPs) were identified. Six of them have already registered on dbSNP database, and 13 SNPs including one non‐synonymous substitution, from asparagine to serine at 638 (N638S) in the exon 15 (position 33205) were identified. All SNPs but one in intron 3 (rs2285666, position 8789) and another in exon 18 (position 39844) were found to be considerably rare among both SARS cases and contacts tested. In subsequent analysis, we therefore chose polymorphisms, and analyzed possible non‐synonymous substitution, excluding rare non‐coding variants among SARS patients and contacts.

###### 

SNPs Within the *ACE2* Gene

  Region                   Position[a](#fn2){ref-type="fn"}   dbSNP rs\# cluster ID         Change of nucleotide (major/minor allele)   Change of amino acid (major/minor allele)   No. of individuals who had the minor allele   
  ------------------------ ---------------------------------- ----------------------------- ------------------------------------------- ------------------------------------------- --------------------------------------------- -----------------------------------
  5′ flanking region       −751                               NEW[b](#fn3){ref-type="fn"}   C/T                                         ---                                         1                                             1
  5′ flanking region       −671                               NEW                           G/A                                         ---                                         1                                             1
  5′ flanking region       −634                               NEW                           C/G                                         ---                                         1                                             0
  ***Intron 3***           ***8789***                         ***rs228566***6               ***A/G***                                   ---                                         ***15***                                      ***32*** [c](#fn4){ref-type="fn"}
  Intron 6                 13286                              rs4646140                     G/A                                         ---                                         0                                             1
  Intron 9                 25082                              NEW                           G/A                                         ---                                         0                                             1
  Intron 10                25424                              NEW                           G/A                                         ---                                         0                                             1
  Intron 10                27418                              rs4646165                     G/A                                         ---                                         0                                             1
  Intron 12                28946                              rs2301693                     C/T                                         ---                                         0                                             2
  Intron 12                29018                              rs2301692                     A/G                                         ---                                         0                                             2
  Intron 14                30816                              NEW                           A/G                                         ---                                         1                                             1
  Intron 14                30867                              rs4646174                     C/G                                         ---                                         0                                             2
  Intron 14                33121                              NEW                           G/C                                         ---                                         1                                             0
  Exon 15                  33205                              NEW                           A/G                                         N/S                                         0                                             1
  Intron 16                36655                              NEW                           G/A                                         ---                                         0                                             1
  Intron17                 38926                              NEW                           C/T                                         ---                                         0                                             1
  Exon 18 (3′‐UTR)         39663                              NEW                           C/G                                         ---                                         0                                             1
  Exon 18 (3′‐UTR)         39705                              NEW                           A/G                                         ---                                         0                                             1
  ***Exon 18 (3′‐UTR)***   ***39844***                        ***NEW***                     ***G/A***                                   ---                                         ***3***                                       ***4*** [c](#fn4){ref-type="fn"}
                                                                                                                                                                                    No. of samples tested = 20                    No. of samples tested = 57

Position numbers indicate distance from 5′ end of the original exon 1.

Newly identified SNPs are shown as NEW.

Minor allele frequencies of the SNPs shown in bold and italic were higher than 0.05.
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Genotype and Allele Frequency of Three SNPs {#sec2-10}
-------------------------------------------

Two SNPs in intron 3 and exon 18 with minor allele frequencies higher than 0.05 and a newly identified non‐synonymous SNP, N638S in exon 15 were analyzed in all samples (Table [IV](#tbl4){ref-type="table"}). Relative positions of these SNPs are shown in Figure [1](#fig1){ref-type="fig"}. Genotyping results by direct sequencing method were confirmed by RFLP or SSCP methods. Because *ACE2* is located to the X chromosome in humans, samples from both males and females were analyzed, respectively. Two possible non‐synonymous SNPs that are shown in the dbSNP database (rs4646116 and rs11798104) were not found in our samples this time. When the antibody‐negative contacts group was compared with antibody‐positive group including SARS cases in either males or females, no difference was observed between the two groups both in regards to genotype and allele frequencies. Comparison between antibody‐positive contacts and SARS cases, and comparison between contacts and non‐contacts did not show any significant differences in genotype and allele frequencies of the tested polymorphisms.

###### 

Genotype and Allele Distribution of Three Single Nucleotide Polymorphisms (SNPs)

                                                                                                        SARS cases   Contacts    Non‐contacts   
  ---------------------- -------- --------------------------------------------------------- ----------- ------------ ----------- -------------- -----------
  Intron 3 (rs2285666)                                                                                                                          
                         Male     Genotype/allele[a](#fn5){ref-type="fn"} no. (frequency)   A           5 (0.38)     4 (0.57)    21 (0.54)      5 (0.31)
                                                                                            G           8 (0.62)     3 (0.43)    18 (0.46)      11 (0.69)
                                                                                            Total no.   13           7           39             16
                         Female   Genotype no. (frequency)                                  A/A         12 (0.39)    4 (0.44)    15 (0.31)      11 (0.33)
                                                                                            A/G         16 (0.51)    3 (0.33)    24 (0.50)      17 (0.52)
                                                                                            G/G         3 (0.10)     2 (0.22)    9 (0.19)       5 (0.15)
                                                                                            Total no.   31           9           48             33
                                  Allele no. (frequency)                                    A           40 (0.65)    11 (0.61)   54 (0.56)      39 (0.59)
                                                                                            G           22 (0.35)    7 (0.39)    42 (0.44)      27 (0.41)
  Exon 15 (N638S)                                                                                                                               
                         Male     Genotype/allele no. (frequency)                           A           13 (1.00)    7 (1.00)    39 (1.00)      17 (1.00)
                                                                                            G           0 (0.00)     0 (0.00)    0 (0.00)       0 (0.00)
                                                                                            Total no.   13           7           39             17
                         Female   Genotype no. (frequency)                                  A/A         31 (1.00)    8 (0.89)    47 (0.98)      33 (1.00)
                                                                                            A/G         0 (0.00)     1 (0.11)    1 (0.02)       0 (0.00)
                                                                                            G/G         0 (0.00)     0 (0.00)    0 (0.00)       0 (0.00)
                                                                                            Total no.   31           9           48             33
                                  Allele no. (frequency)                                    A           62 (1.00)    17 (0.94)   95 (0.99)      66 (1.00)
                                                                                            G           0 (0.00)     1 (0.06)    1 (0.01)       0 (0.00)
  Exon 18 (3′‐UTR)                                                                                                                              
                         Male     Genotype/allele no. (frequency)                           G           12 (0.92)    7 (1.00)    37 (0.95)      17 (1.00)
                                                                                            A           1 (0.08)     0 (0.00)    2 (0.05)       0 (0.00)
                                                                                            Total no.   13           7           39             17
                         Female   Genotype no. (frequency)                                  G/G         27 (0.87)    8 (0.89)    46 (0.96)      29 (0.88)
                                                                                            A/G         4 (0.13)     1 (0.11)    2 (0.04)       4 (0.12)
                                                                                            A/A         0 (0.00)     0 (0.00)    0 (0.00)       0 (0.00)
                                                                                            Total no.   31           9           48             33
                                  Allele no. (frequency)                                    G           58 (0.94)    17 (0.94)   94 (0.98)      62 (0.94)
                                                                                            A           4 (0.06)     1 (0.06)    2 (0.02)       4 (0.06)

Genotype distribution is the same as allele distribution in male.
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DISCUSSION {#sec1-4}
==========

During the worldwide outbreak of SARS in 2003, a subset (about 20%--30%) of SARS patients required mechanical ventilation, having developed pneumonia. The fatality rate was 11%, although the majority of patients recovered without unfavorable outcome \[Peiris et al., [2003b](#bib20){ref-type="ref"}\]. As a natural consequence, asymptomatic individuals produce antibodies against SARS‐CoV in their sera \[Ip et al., [2004](#bib11){ref-type="ref"}; Woo et al., [2004](#bib25){ref-type="ref"}\]. In one of the studies, it was shown that 2.3% of contacts who did not develop clinical SARS had serum antibody titer over the threshold \[Ip et al., [2004](#bib11){ref-type="ref"}\], and this implies the presence of asymptomatic individuals.

We hypothesized that the functional polymorphism of ACE2, which is considered as being a virus receptor of SARS‐CoV, might influence the clinical history of SARS‐CoV infection at least in part. This is because, a variation of the co‐receptor to HIV, CCR5‐Δ32 where allele frequency is approximately 10% in the European population \[Martinson et al., [1997](#bib18){ref-type="ref"}\], has been well known to resist HIV infection and alter its clinical course \[Dean et al., [1996](#bib3){ref-type="ref"}; Liu et al., [1996](#bib17){ref-type="ref"}; Samson et al., [1996](#bib21){ref-type="ref"}\].

Using the PCR‐based cloning procedure, we identified for the first time an alternative exon upstream of the original exon 1 of *ACE2* that is expressed in various organs, including the lung and trachea, primary‐cultured bronchial epithelial cells, and the small intestine. These are considered to be important replication sites of SARS‐CoV \[Haagmans et al., [2004](#bib8){ref-type="ref"}\]. Both 5′‐and 3′‐ends of the intron between the new alternative exon and the original exon 1 followed the GT/AG rule of Breathnach and Chambon \[[1981](#bib1){ref-type="ref"}\]. Although the organ specificity of the transcripts was not confirmed in this study due to the limitation of non‐quantitative PCR amplification, implication of the new exon was definitely shown in the lung and small intestine. Also, we found the extended region of the original exon 1, 65 bp on the 5′ side. Neither the new alternative exon nor the new extended region of exon 1 gave rise to a new coding region and they were considered as 5′‐untranslated region.

It was recently reported that genetic variations of ACE2 did not affect SARS susceptibility or outcome in Hong Kong \[Chiu et al., [2004](#bib2){ref-type="ref"}\]. In that study, five intronic SNPs (rs2106809, rs2285666, rs4646142, rs714205, and rs2074192) were chosen and analyzed in a case‐control manner, based on the previously known exon‐intron structure and SNPs already registered in the database. By contrast, we attempted to analyze not only previously known SNPs but also variations newly identified among actual SARS patients and contacts. Based on the information from the exon‐intron structure of *ACE2* cloned by ourselves, we searched for nucleotide sequences in all the exons including the new alternative exon and the corresponding 5′‐flanking region, which are thought to contain promoters of the new exon and the original exon 1. We found one novel non‐synonymous substitution N638S and 18 non‐coding SNPs including two relatively common SNPs with minor allele frequency higher than 5%. We selected these SNPs and analyzed them furthermore in a case‐control manner, because, while they are rare occurrence, non‐synonymous substitution may directly modulate the function of the protein, and because relatively common SNPs can often be used as markers to ascertain a causative variation. Of 19 SNPs found in this study, 13 were new polymorphisms, 3 of which were located in 3′‐UTR. Two possible non‐synonymous SNPs in dbSNP database were not found in the population tested. Judging from the results so far obtained in this case‐control study, there was no statistical evidence that ACE2 polymorphisms affect SARS infection or alter its clinical course. However, type II error was not negligible because of a relatively small size of samples tested.

Taking also into consideration, the results from a previous study of *ACE2* polymorphisms by others \[Chiu et al., [2004](#bib2){ref-type="ref"}\], it is unlikely that the genetic defect of ACE2 is involved in the disease resistance that has been shown in CCR5‐Δ32 in HIV‐1 infection cases. Nevertheless, this newly identified alternative 5′‐untranslated exon expressed in the lung, and also newly recognized polymorphisms in this study might be of great help concerning investigations into the regulation of *ACE2* gene expression and the possible significance of the variations in further more in‐depth studies.
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